Hydroxychloroquine offers „no beneficial effect“ in hospitalized patients with COVID-19, researchers at the University of Oxford In England announced Friday.
June 5 (UPI) — Hydroxychloroquine offers „no beneficial effect“ in hospitalized patients with COVID-19, researchers at the University of Oxford In England announced Friday.
Just over one in four patients who received the anti-malaria drug died within 28 days of starting treatment, while slightly less than one in four of those who received usual care — basically supportive management of heart and lung symptoms — died within that time frame, researchers heading up the RECOVERY trial said.
The findings are based on an analysis of data from 80 percent of the study participants, they said.
„These data convincingly rule out any meaningful mortality benefit of hydroxychloroquine in patients hospitalized with COVID-19,“ they said in a statement. „Full results will be made available as soon as possible,“ they said.
„There has been huge speculation and uncertainty about the role of hydroxychloroquine as a treatment for COVID-19, but an absence of reliable information from large randomized trials,“ Dr.
